Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to validate the efficacy and safety of subthreshold laser photocoagulation on high-risk macular drusen in early age-related macular degeneration which has a high risk of conversion to exudative AMD.
SAVE Study (Stop Early Age-related Macular Degeneration form Vision Loss Eternally)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention-"Device:_Laser" | Experimental |
|
|
| Control | No Intervention | Contralateral eye |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Subthreshold Laser Photocoagulation | Procedure | Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in drusen size | 3 month interval |
| Measure | Description | Time Frame |
|---|---|---|
| Best Corrected Visual Acuity (BCVA) | ETDRS and Snellen visual acuity measurement | 3 months interval |
| Change in drusen distribution | 3 month interval |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kyu Hyung Park, M.D., Ph.D. | Seoul National University Bundang Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Bundang Hospital | Seongnam | Gyunggi-do | 463-707 | South Korea |
undecided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D015593 | Retinal Drusen |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| intravitreal Anti-VEGF injection | Drug | To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year. |
|
| Subthreshold Laser | Device |
|
| Change in autofluorescence | 3 month interval |
| Choroidal Neovascularization | 3 months interval |
| Contrast Sensitivity | Contrast Sensitivity Test | 3 months interval |